STOCKS TELEGRAPH

Tag: GeoVax Labs

  • GeoVax Labs (GOVX) Gains Pre-Market Momentum With Critical Vaccine Trial Award

    GeoVax Labs (GOVX) Gains Pre-Market Momentum With Critical Vaccine Trial Award

    GeoVax Labs, Inc. (NASDAQ: GOVX) shares have observed a notable rise following the award of a substantial trial contract. During the pre-market session, GOVX shares surged by 8.42%, reaching $2.06, building on a previous session’s impressive increase of 69.64%, which closed at $1.90.

    Finances For The Clinical Trial

    The funding from the Rapid Response Partnership Vehicle, or RRPV, will help develop GeoVax’s (GOVX) next-generation COVID-19 vaccine, GEO-CM04S1. The RRPV is funded by the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS).

    This agreement includes a clinical research with 10,000 participants in Phase 2b. Its goal is to compare the safety, immunogenicity, and efficacy of GEO-CM04S1 to an mRNA COVID-19 vaccination that has received FDA approval. The trial preparations are underway, with BARDA committing approximately $24.3 million initially, potentially increasing to $45 million.

    This funding will cover the manufacturing of clinical materials and regulatory support for the Phase 2b trial. Additional awards from BARDA’s Clinical Studies Network will provide around $343 million to execute the trial using GeoVax’s vaccine, under the Project NextGen program.

    Innovative Vaccine Development

    The funding supports both GeoVax’s MVA platform for infectious illnesses and provides essential resources for the development of GEO-CM04S1. Although first-generation COVID-19 vaccinations were effective during the height of the epidemic, their protective range and longevity are limited, requiring regular updates.

    By promoting long-lasting neutralizing antibody and T-cell-based immunity against both present and future SARS-CoV-2 variants, GEO-CM04S1 seeks to overcome these constraints. The vaccine developed by GeoVax has continuously shown strong immune responses and has the potential to provide long-lasting and comprehensive clinical protection. It is expected that the start of the Phase 2b research will confirm the benefits and effectiveness of GeoVax’s novel technology.

    Funding for this initiative is part of Project NextGen, a $5 billion effort by HHS to develop new vaccines and therapeutics offering broader and more enduring protection against COVID-19 than those provided by the first-generation vaccines.

  • GeoVax Labs (GOVX) Stock Makes Stellar Gains

    GeoVax Labs Inc. (NASDAQ: GOVX) is a biotechnology company that specializes in developing and commercializing treatments for various cancers and viral conditions. Many describe GeoVax as being at the forefront of the global battle against several deadly viruses, including the Zika condition. It has recently been making terrific strides in the market, due to some hot updates.

    GOVX Rallies with Zika Patent Acquisition

    The big news for GeoVax Labs Inc. (GOVX) relates to its recent achievement of finally getting a patent for its Zika virus treatment from the US Patent and Trademark Office. The development is a major milestone for the company, as it protects its IP in the market, and makes the company a formidable name in the global fight against the Zika virus. The particular object of this patent protection is the modified vaccinia Ankara platform, which the company expects to be a breakthrough against the Zika virus, along with future strains. Its safety record stands as being spectacular, based on the studies performed.

    GeoVax to Present at the BioGEO Investor and CEO Conference for 2023

    Another potential catalyst that has GOVX stock in the spotlight of the market may link to its upcoming spot in the biotech world’s much-awaited BioGEO Conference, where CEOs of top firms will be interacting with investors and industry stakeholders. The recent patent approval is highly likely to be discussed within the venue, along with other pipeline-related developments that GeoVax has undertaken in recent years. Most important, however, would be its future roadmap, and its ability to execute these ambitions.

    Conclusion

    GOVX stock has been on a roll, and recent updates have been fueling this upward growth. With solid fundamentals and bright prospects, the stock seems to be gaining quite some exposure among market players. Only time will ultimately tell how far this beast may actually fly.

  • Top key players of Biotech Industry

    Top key players of Biotech Industry

    It is evident with so many people focused on COVID-19 that biotech stocks with coronavirus vaccines and treatments have gained a lot of attention.

    The Pfizer and BioNTech vaccine is developed on mRNA science, more straightforward, quicker, and cheaper to produce than standard vaccines. Even so, amid the enormous capital and expertise of Pfizer, the large pharmaceutical firm has failed to reach the production goals it initially set for the vaccine, needing to cut the original 100 million doses in 2020 to 50 million last month.

    The development issues are not restricted to vaccines for Covid-19 either. The FDA authorized the use of antibody drugs to treat Covid-19 last month, for example, complicated to develop. Other indications include diagnostics and cell therapies are in development. Flowing are the key performers from the Biotech sectors in yesterday’s market session.

    Xenetic Biosciences Inc. (NASDAQ:XBIO) shares were trading up 193.52% at $3.17 at the time of writing on Wednesday following declaration that it saw positive data from its partner PJSC Pharmsynthez about its pivotal Phase 3 clinical study leveraging PolyXen to develop a treatment for anemia in patients with chronic kidney disease (CKD).

    Xenetic Biosciences Inc. (NASDAQ:XBIO) share price went from a low point around $0.44 to briefly over $1.85 in past 52 weeks, though shares have since pulled back to $3.17. XBIO market cap has remained high, hitting $20.45M at the time of writing, giving it price-to-sales ratio of more than 60.

    If we look at the recent analyst rating XBIO, Maxim Group initiated coverage on XBIO shares with a Buy rating.

    Moderna Inc. (MRNA) last closed at $156.59, in a 52-week range of $17.68 to $178.50. The healthcare firm recently declared that the Swiss Federal Government has increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273. Analysts have a consensus price target of $122.60.

    GeoVax Labs Inc. (GOVX) stock soar by 79.06% to $5.73. The company on November 30, 2020 reported license agreement with NIH to support continued advancements in vaccine development. The most recent rating by Maxim Group, on November 19, 2020, is at a Buy.

    Intec Pharma Ltd (NASDAQ:NTEC) Shares headed rising, higher as much as 34.10% after declaring that it has entered into a feasibility agreement with GW Research Limited, London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program.. The most recent rating by Ladenburg Thalmann, on December 09, 2020, is at a Buy.

    Atossa Therapeutics Inc. (NASDAQ:ATOS) fall -39.03% after losing more than -$0.56 on Wednesday after the company reported pricing of $20.0 million underwritten public offering.

    Sorrento Therapeutics Inc. (SRNE) last closed at $8.21, in a 52-week range of $1.55 to $19.39. The company reported that it received US FDA clearance to proceed with Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in healthy volunteers and in newly diagnosed COVID-19 Patients.

    Greenwich LifeSciences Inc. (GLSI) stock soar by 998.35% to $57.10 after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.

    Jaguar Health Inc. (NASDAQ:JAGX) Shares headed falling, lower as much as -11.45%. The most recent rating by Rodman & Renshaw, on July 11, 2017, is at a Buy.

    Lipocine Inc. (NASDAQ:LPCN) fall -21.43% after losing more than -$0.36 on Wednesday following the announcement from the company that the U.S. Food and Drug Administration has granted tentative approval to TLANDO

    Tonix Pharmaceuticals Holding Corp. (TNXP) last closed at $0.64, in a 52-week range of $0.39 to $2.46. On December 3, 2020, the firm declared positive phase 3 RELIEF study results for TNX-102 SL 5.6 mg in Fibromyalgia.

    SELLAS Life Sciences Group Inc. (SLS) stock soar by 73.17% to $6.39. The company on December 7, 2020 revealed an exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China. The most recent rating by Oppenheimer, on November 01, 2018, is at an Outperform.

    AIkido Pharma Inc. (NASDAQ:AIKI) Shares headed rising, higher as much as 4.07% after declaring the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer.

    Celsion Corporation (NASDAQ:CLSN) rose 12.90% after gaining more than $0.08 on Wednesday.

    ADMA Biologics Inc. (ADMA) last closed at $2.22, in a 52-week range of $1.45 to $4.65. The firm recently announced $100 million credit facility loan amendment with perceptive advisors.

    Onconova Therapeutics Inc. (ONTX) stock soar by 1.75% to $0.32. On November 23, 2020, the company reported the filing of an investigational new drug application for Multi-kinase CDK4/6 Inhibitor ON 123300. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.